In short
COR-1167 sodium is an investigational substance being studied for worsening heart failure. It is a corticotrophin releasing factor 2 (CRF2) agonist given by subcutaneous injection. One Phase 2 trial, the CRAFT-WHF study, has been registered to evaluate three doses of COR-1167 against placebo in 300 participants. The trial is currently suspended.
Key points
- COR-1167 sodium is an investigational CRF2 agonist for worsening heart failure.
- The registered Phase 2 trial planned to enrol 300 participants.
- The trial compares three doses of COR-1167 with placebo, given subcutaneously once daily for 4 weeks.
- Primary outcomes include natriuresis, body weight, NT-proBNP, KCCQ-TSS and LAVi.
- The CRAFT-WHF study is currently suspended.
What is COR-1167 sodium?
COR-1167 sodium is an investigational substance that acts as a corticotrophin releasing factor 2 (CRF2) agonist. It is being developed as a potential treatment for worsening heart failure (WHF). No marketing authorisation is mentioned in the available registry data, so it remains an investigational medicine.
How does COR-1167 sodium work?
COR-1167 sodium is designed to stimulate the corticotrophin releasing factor 2 receptor. The trial is evaluating whether this action influences natriuresis, body weight, levels of N-terminal pro B-type natriuretic peptide (NT-proBNP), the Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS), and Left Atrial Volume Index (LAVi). The provided supplementary source does not describe the mechanism of action of COR-1167 sodium.
Which conditions is COR-1167 sodium studied for?
- Worsening heart failure (WHF) — a condition in which heart failure symptoms become more severe and require additional treatment. The CRAFT-WHF study is evaluating COR-1167 sodium in this population.
How is COR-1167 sodium given?
COR-1167 sodium is given as a subcutaneous injection. In the registered trial, three doses of COR-1167 were to be administered once daily for 4 weeks, compared with a placebo solution for injection.
What do the clinical trials show?
One Phase 2 trial, the CRAFT-WHF study (NCT06815471), has been registered for COR-1167 sodium in worsening heart failure. The trial planned to enrol 300 participants. It is an interventional study with a parallel design comparing three doses of COR-1167 against placebo. The trial is currently suspended.
The primary endpoints are the individual assessments of the dose-effect relationship of COR-1167 on natriuresis, body weight, NT-proBNP, KCCQ-TSS and LAVi. The study was designed to administer the study drug subcutaneously once daily for 4 weeks.
What side effects are known?
No side effects for COR-1167 sodium are reported in the available trial registry data or the supplementary source. The supplementary source describes omega-3 fatty acid compounds and does not mention COR-1167 sodium.